Log on / register
BioMed Central home | Journals A-Z | Feedback | Support | My details
Open AccessHighly AccessReview

Inflammation: a way to understanding the evolution of portal hypertension

María-Angeles Aller1 email, Jorge-Luis Arias2 email, Arturo Cruz1,3 email and Jaime Arias1 email

Surgery I Department. Medical School, Complutense University, 28040 Madrid, Spain

Psychobiology Laboratory, School of Psychology, University of Oviedo, Asturias, Spain

General Surgery Department, Virgen de la Luz General Hospital, 16002 Cuenca, Spain

author email corresponding author email

Theoretical Biology and Medical Modelling 2007, 4:44doi:10.1186/1742-4682-4-44

Published: 13 November 2007

Abstract

Background

Portal hypertension is a clinical syndrome that manifests as ascites, portosystemic encephalopathy and variceal hemorrhage, and these alterations often lead to death.

Hypothesis

Splanchnic and/or systemic responses to portal hypertension could have pathophysiological mechanisms similar to those involved in the post-traumatic inflammatory response.

The splanchnic and systemic impairments produced throughout the evolution of experimental prehepatic portal hypertension could be considered to have an inflammatory origin. In portal vein ligated rats, portal hypertensive enteropathy, hepatic steatosis and portal hypertensive encephalopathy show phenotypes during their development that can be considered inflammatory, such as: ischemia-reperfusion (vasodilatory response), infiltration by inflammatory cells (mast cells) and bacteria (intestinal translocation of endotoxins and bacteria) and lastly, angiogenesis. Similar inflammatory phenotypes, worsened by chronic liver disease (with anti-oxidant and anti-enzymatic ability reduction) characterize the evolution of portal hypertension and its complications (hepatorenal syndrome, ascites and esophageal variceal hemorrhage) in humans.

Conclusion

Low-grade inflammation, related to prehepatic portal hypertension, switches to high-grade inflammation with the development of severe and life-threatening complications when associated with chronic liver disease.


© 1999-2010 BioMed Central Ltd unless otherwise stated. Part of Springer Science+Business Media.